Psoriasis induced by infliximab in a Saudi patient with ankylosing spondylitis.
Although the therapeutic uses of tumor necrosis factor alpha antagonists have added a highly effective treatment of ankylosing spondylitis and associated spondyloarthropathies, they are associated with many untoward effects. We describe a Saudi patient with ankylosing spondylitis who developed severe psoriatic lesions in treatment with infliximab. He had no personal, or family history of psoriasis, and no other triggering factors known to induce psoriasis.
Alabed
Iehab B
IB
Department of Internal Medicine, Rheumatology Division, King Fahad Medical City, PO Box 4756, Riyadh, Kingdom of Saudi Arabia. aba1974@hotmail.com
Qushmaq
Khalid A
KA
Khan
Muhammad A
MA
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008297:Male; D011565:Psoriasis / Q000139:chemically induced*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab